May 5, 2022
News
April 11, 2022
Artiva Biotherapeutics Announces Agreement with Merck to Evaluate Combinations of NK Cells with Tri-Specific NK-Cell Engagers
March 21, 2022
Artiva Biotherapeutics Appoints Laura Bessen, M.D., to Its Board of Directors
January 4, 2022
Artiva Biotherapeutics Strengthens Leadership Team with the Appointment of Christopher Horan as Chief Technical Operations Officer
October 21, 2021
Artiva Biotherapeutics to Present Preclinical Data for AB-201, a HER2-Targeting CAR-NK Cell Therapy, at SITC 36th Annual Meeting
September 30, 2021
Artiva Biotherapeutics Demonstrates Its Commitment to Corporate Social Responsibility by Joining Pledge 1% Movement
August 12, 2021
Artiva Biotherapeutics Establishes U.S. Research and Manufacturing Facility for NK Cell Therapy Pipeline Development and Clinical Supply
May 19, 2021
Artiva Biotherapeutics Appoints Two New Independent Members to Its Board of Directors
April 6, 2021
Artiva Biotherapeutics Appoints Michael E. Faerm as Chief Financial Officer
February 26, 2021